Copyright
©2014 Baishideng Publishing Group Inc.
World J Gastroenterol. Aug 28, 2014; 20(32): 11400-11405
Published online Aug 28, 2014. doi: 10.3748/wjg.v20.i32.11400
Published online Aug 28, 2014. doi: 10.3748/wjg.v20.i32.11400
Figure 2 The effects of tolvaptan on serum sodium (mean ± SE) in patients with and without hyponatremia (n = 21 and n = 18, respectively).
Tolvaptan (15 mg/d, 5-14 d) treatment (black column) significantly increased serum sodium concentration [t (40) = -4.029, bP < 0.01 vs before treatment group] in patients with hyponatremia, but not in patients without hyponatremia [t (32) = 1.545, P > 0.05 (NS)]. NS: Not significant.
- Citation: Zhang X, Wang SZ, Zheng JF, Zhao WM, Li P, Fan CL, Li B, Dong PL, Li L, Ding HG. Clinical efficacy of tolvaptan for treatment of refractory ascites in liver cirrhosis patients. World J Gastroenterol 2014; 20(32): 11400-11405
- URL: https://www.wjgnet.com/1007-9327/full/v20/i32/11400.htm
- DOI: https://dx.doi.org/10.3748/wjg.v20.i32.11400